assess fully published cost-effectiveness studies comparing the new agents docetaxel, paclitaxel, vinorelbine, gemcitabine … effective compared with other platinum-based regimens (paclitaxel, docetaxel and vinorelbine). In one study, pemetrexed …-line treatment, docetaxel was cost effective compared with best supportive care; erlotinib was cost effective compared with placebo …

) from the perspective of the UK NHS, based on the resources and outcomes from the pivotal clinical study comparing docetaxel … the difference in mean survival between the docetaxel group and the BSC group was calculated as 3.82 months. Measurable … incremental costs for the docetaxel group were largely driven by drug acquisition and administration. These cost drivers, as well …

practice are regimens such as cisplatin or carboplatin combined with paclitaxel, vinorelbine, gemcitabine, docetaxel or … analyses have been conducted on paclitaxel in NSCLC and most have focused on its use in combination with cisplatin. In terms of … clinical efficacy, paclitaxel-cisplatin combinations achieved significantly higher response rates than teniposide plus …

Paclitaxel belongs to the group of antitumor agents called the taxanes. Its efficacy in advanced ovarian cancer has … year. Paclitaxel plus carboplatin has similar efficacy to paclitaxel plus cisplatin. There is now consensus that paclitaxel … particular combination employed may vary between institutions and geographical regions, although paclitaxel plus carboplatin is …